Comparison of the potentiating effects of nicorandil and its denitrated metabolite (SG-86) on the adenosine-induced vasodepression

Fundamental and Clinical Pharmacology

Volumn 12, Issue 5, 1998, Pages 492-497

  Sakai, K ^a   Saito, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adenosine induced vasodepression; Enhancement; K(ATP) channel activation; Nicorandil; SG 86 (a denitrated metabolite of nicorandil)

Indexed keywords

ACETYLCHOLINE; ADENOSINE; GLIBENCLAMIDE; N (2 HYDROXYETHYL)NICOTINAMIDE; NICORANDIL; NITROSAMINE; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CHANNEL GATING; DOSE RESPONSE; DRUG POTENTIATION; DRUG STRUCTURE; HEART RATE; INDUCED HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032421239     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00977.x     Document Type: Article

References (26)

1. Aversano T, Quyang P, Silverman H. Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation. Circ Res 1991 ; 69 : 618-22
2. Belloni FL, Hintze TH. Glibenclamide attenuates adenosine-induced bradycardia and coronary vasodilatation. Am J Physiol 1991 ; 26 : H720-7
3. Cavero I, Mondot S, Mestre M. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. J Pharmacol Exp Ther 1989 ; 248 : 1261-8
4. Clapham JC, Hamilton TC, Longman SD, Buckinham RE, Campbell CA. Antihypertensive and haemodynamic properties of the potassium channel activating (-)-enantiomer of cromakalim in animal models. Arzneim Forsch Drug Res 1991 ; 41 : 385-91
5. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunter K, Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990 ; 247 : 1341-4
6. Frydman A. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992 ; 20 : S34-44
7. 2 receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein. Eur J Pharmacol 1993 ; 236 : 255-62
8. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989 ; 20 : 1-9
9. Inoue T, Kanmura Y, Fujisawa K, Itoh T, Kuriyama H. Effects of 2-nicotinamidoethyl nitrate (nicorandil; SG-75) and its derivatives on smooth muscle cells of the canine mesenteric artery. J Pharmacol Exp Ther 1984 ; 229 : 793-802
10. Ishibashi T, Hamaguchi M, Imai S. 2-Nicotinamidoethyl acetate (SG-209) is a potassium channel opener: structure activity relationship among nicorandil derivatives. Naunyn-Schmiedeberg's Arch Pharmacol 1991 ; 344 : 235-9
11. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990 ; 4 : 1075-88
12. Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its haemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992 ; 20 : S93-102
13. Lefkowitz RJ, Hoffman BB, Taylor P. The autonomie and somatic motor nervous systems. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon PW, Gilman AG, eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1995. p 127-8
14. Mubagwa K, Mullane K, Flameng W. Role of adenosine in the heart and circulation. Cardiovasc Res 1996 ; 32 : 797-813
15. Saito K, Sakai K. Enhancement of the vasodepressor response to adenosine by nicorandil in rats: comparison with cromakalim. Fundam Clin Pharmacol 1998 ; 12 : 37-43
16. Sakai K, Ohba Y, Akima M, Kamiyama H, Hinohara Y, Nakano H. Pharmacodyamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75). Jpn J Pharmacol 1980 ; 30 : 881-90
17. Sakai K, Akima M, Hinohara Y, Obatake N. Hypotensive effects and biotransformation of nicorandil, a new antianginal agent, administered to rats by different routes: comparison with nitroglycerin and isosorbide dinitrate. J Pharm Pharmacol 1984 ; 36: 175-81
18. Sakai K. Nicorandil: animal pharmacology. Am J Cardiol 1989 ; 63 : 2J-10
19. Sakai K, Akima M, Saito K. Differential effects of nicorandil on the vasodepressor responses to vasoactive polypeptides administered intravenously to rats. J Pharm Pharmacol 1998 ; 50 : 1-4
20. Sakai K, Akima M, Kamachi S, Moriyasu M, Kitajima S. Relationship among the cardiovascular effects and plasma levels of nicorandil, and vascular cGMP formation in conscious rats. J Pharm Pharmacol 1998 ; 50 : 661-6
21. Sakai K, Saito K, Akima M. Synergistic effect of calcitonin gene-related peptide on adenosine-induced vasodepression in rats. Eur J Pharmacol 1998 ; 344 : 153-9
22. ATPchannels. Eur J Pharmacol 1998 ; 345 : 279-84
23. Satoh K, Yamada H, Yoneyama F, Taira N. The group at C2 of N-ethylnicotinamide determines the vasodilator potencies and mechanisms of action of nicorandil and its congeners in canine coronary arteries. Naunyn-Schmiedeberg's Arch Pharmacol 1991 ; 344 : 589-95
24. Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75). Clin Exp Pharmacol Physiol 1979 ; 6 : 301-16
25. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987 ; 10 : S1-9
26. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989 ; 63 : 18J-24